YolTech and Salubris Sign Agreement for YOLT-101 Development and Marketing in Mainland China
Wednesday, August 28, 2024
YolTech Therapeutics, a leading clinical-stage gene editing company, has signed an exclusive licensing agreement with Salubris Pharmaceuticals.
YOLT-101 is a liver-targeted base editing therapy currently being tested in an IIT clinical trial for patients with high-risk heterozygous familial hypercholesterolemia (FH), established atherosclerotic cardiovascular disease (ASCVD), and uncontrolled LDL-C levels despite standard oral treatments.
This one-time treatment aims to permanently inhibit the PCSK9 gene in the liver to lower LDL-C levels.
This agreement allows Salubris to develop and commercialise YolTech’s innovative PCSK9-targeting base editing therapy, YOLT-101, in Mainland China. The total deal is valued at RMB 1.035 billion, with YolTech set to receive tiered royalties based on net sales.
As part of the agreement, Salubris will have exclusive rights to develop and market YOLT-101 in Mainland China, excluding Hong Kong, Macau, and Taiwan.
YolTech will receive an upfront payment and development milestone of RMB 205 million, alongside up to RMB 830 million in commercial milestone payments. Additionally, Salubris will pay tiered royalties based on the net sales of YOLT-101 in the specified region.
YolTech will continue with the preclinical development of YOLT-101, while Salubris will be responsible for clinical trials in the licensed areas.
YolTech are delighted to collaborate with Salubris, a company renowned for its strengths in clinical development and commercialisation, especially in cardiovascular treatments.
Preclinical data for YOLT-101 are highly promising, showing significant and long-lasting reductions in LDL-C levels with a single dose in non-human primate models.
This partnership will accelerate the development and commercialisation of YOLT-101 in Mainland China, enabling us to deliver this groundbreaking therapy to patients in need.
Source: prnewswire.com
